Neurological Biomarkers Market Flourishes with Market Analysis, Growth Drivers, and a Strong Demand Forecast

The new report published by The Business Research Company, titled Neurological Biomarkers Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the neurological biomarkers market size has grown rapidly in recent years. It will grow from $9.46 billion in 2023 to $10.63 billion in 2024 at a compound annual growth rate (CAGR) of 12.4%. The neurological biomarkers market size is expected to see rapid growth in the next few years. It will grow to $17.18 billion in 2028 at a compound annual growth rate (CAGR) of 12.7%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12677&type=smp

Rising Prevalence Of Neurological Diseases Fuels Momentum In Neurological Biomarker Market
The increasing prevalence of neurological diseases is expected to propel the growth of the neurological biomarker market going forward. Neurological illnesses affect the brain, spinal cord, and all of the body's other nerves. Parkinson's disease is a neurodegenerative disorder affecting the neurological system and the areas of the body that are under the control of the nerves. Neurological biomarkers help provide an early diagnosis of Parkinson's disease using pathological, biochemical, and genetic testing. For instance, in December 2022, according to the Parkinson's Foundation, a US-based non-profit organization, the number of new diagnoses of Parkinson's disease reached 90,000 in 2022, up from 60,000 per year in 2021. Therefore, the increasing prevalence of neurological diseases is driving the growth of the neurological biomarker market.

Strategic Collaborations Drive Innovation In Neurological Biomarkers Market
Major companies operating in the neurological biomarkers market are forming partnerships to develop new products and strengthen their positions in the market. Collaborations and partnerships in the neurological biomarkers market foster innovation, leverage complementary expertise, and accelerate the development and commercialization of advanced therapies by combining resources and capabilities. For instance, in July 2022, NeuroSense Therapeutics Ltd., an Israel-based company developing treatments for severe neurodegenerative diseases partnered with NeuraLight, an Israel-based company developing objective and sensitive biomarkers for neurological disorders. This collaboration is to identify oculometric indicators for Amyotrophic Lateral Sclerosis (ALS) through the application of AI (Artificial Intelligence) and ML (Machine Learning). The partnership, which comes after NeuraLight's $25 million Series A financing, is to enhance the discovery and application of ALS digital indicators in a parallel study. This will be the collaboration's first clinical trial. The partnership is centered on the application of oculometric digital indicators, which may allow for patient classification and boost clinical trial success rates.

The neurological biomarkers market covered in this report is segmented -

1) By Product: Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, Other Products
2) By Application: Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Schizophrenia, Depression, Multiple Sclerosis, Spinal Muscular Atrophy
3) By End-User: Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12677&type=discount

Major companies operating in the neurological biomarkers market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals.

Contents of the report:
1. Executive Summary
2. Neurological Biomarkers Market Report Structure
3. Neurological Biomarkers Market Trends And Strategies
4. Neurological Biomarkers Market - Macro Economic Scenario
5. Neurological Biomarkers Market Size And Growth
…..
27. Neurological Biomarkers Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.